Published in Int J Radiat Oncol Biol Phys on October 05, 2005
Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer | NCT00970502
The pattern of failure after reirradiation of recurrent squamous cell head and neck cancer: implications for defining the targets. Int J Radiat Oncol Biol Phys (2009) 1.10
Stereotactic body radiation therapy in the re-irradiation situation--a review. Radiat Oncol (2013) 1.08
Simple carotid-sparing intensity-modulated radiotherapy technique and preliminary experience for T1-2 glottic cancer. Int J Radiat Oncol Biol Phys (2009) 1.01
IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer. Strahlenther Onkol (2010) 0.95
The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy. Am J Clin Oncol (2011) 0.94
Boron neutron capture therapy outcomes for advanced or recurrent head and neck cancer. J Radiat Res (2013) 0.90
Cetuximab and radiation for primary and recurrent squamous cell carcinoma of the head and neck (SCCHN) in the elderly and multi-morbid patient: a single-centre experience. Head Neck Oncol (2010) 0.89
Reirradiation with alternating docetaxel-based chemotherapy for recurrent head and neck squamous cell carcinoma: update of a single-center prospective phase II protocol. Strahlenther Onkol (2010) 0.87
Reirradiation of head and neck cancer focusing on hypofractionated stereotactic body radiation therapy. Radiat Oncol (2011) 0.87
Increasing frequency of reirradiation studies in radiation oncology: systematic review of highly cited articles. Am J Cancer Res (2013) 0.86
A nomogram to predict loco-regional control after re-irradiation for head and neck cancer. Radiother Oncol (2014) 0.85
Outcome after re-irradiation of head and neck cancer patients. Strahlenther Onkol (2010) 0.81
Survival outcomes of patients treated with hypofractionated stereotactic body radiation therapy for parotid gland tumors: a retrospective analysis. Front Oncol (2012) 0.80
Cesium-131 brachytherapy in high risk and recurrent head and neck cancers: first report of long-term outcomes. J Contemp Brachytherapy (2015) 0.79
A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol (2012) 0.79
Outcomes of patients with loco-regionally recurrent or new primary squamous cell carcinomas of the head and neck treated with curative intent reirradiation at Mayo Clinic. Radiat Oncol (2016) 0.79
Angiogenesis in head and neck cancer: a review of the literature. J Oncol (2011) 0.78
A simple strategy to decrease fatal carotid blowout syndrome after stereotactic body reirradiaton for recurrent head and neck cancers. Radiat Oncol (2013) 0.78
Reirradiation of recurrent salivary gland malignancies with fractionated stereotactic body radiation therapy. J Radiat Oncol (2012) 0.78
The incidence of cerebrovascular accidents and second brain tumors in patients with pituitary adenoma: a population-based study. Neurooncol Pract (2014) 0.76
Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma. Cancer Med (2016) 0.76
Reirradiation using robotic image-guided stereotactic radiotherapy of recurrent head and neck cancer. J Radiat Res (2016) 0.75
Reirradiation of head and neck cancer in the era of intensity-modulated radiotherapy: patient selection, practical aspects, and current evidence. Radiat Oncol J (2017) 0.75
A surveillance study of the current status of reirradiation and patterns of practice. J Radiat Res (2016) 0.75
A Retrospective Evaluation of Clinical Profile of Second Primary Head and Neck Cancer. J Clin Diagn Res (2016) 0.75
A retrospective study of head and neck re-irradiation for patients with recurrent or second primary head and neck cancer: the McGill University experience. J Otolaryngol Head Neck Surg (2015) 0.75
Impact of Flap Reconstruction on Radiotoxicity After Salvage Surgery and Reirradiation for Recurrent Head and Neck Cancer. Ann Surg Oncol (2016) 0.75
Chemical and Radiation-Associated Jaw Lesions. Dent Clin North Am (2016) 0.75
Reirradiation with IMRT for recurrent head and neck cancer: A single-institutional report on disease control, survival, and toxicity. Rep Pract Oncol Radiother (2017) 0.75
Locoregionally recurrent head and neck squamous cell carcinoma: incidence, survival, prognostic factors, and treatment outcomes. Oncotarget (2017) 0.75
What should we expect from robotic surgery for second primary oropharyngeal cancer? Eur Arch Otorhinolaryngol (2017) 0.75
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol (2004) 5.06
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol (2008) 5.04
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol (2004) 3.67
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol (2005) 3.28
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18
Is patient travel distance associated with survival on phase II clinical trials in oncology? J Natl Cancer Inst (2003) 3.09
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. J Clin Oncol (2008) 3.02
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol (2003) 2.85
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol (2012) 2.76
Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol (2013) 2.73
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst (2006) 2.61
Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol (2004) 2.51
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2005) 2.47
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol (2009) 2.45
Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol (2007) 2.44
Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol (2008) 2.40
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol (2009) 2.32
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol (2005) 2.18
Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer (2008) 2.06
Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res (2009) 2.03
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res (2009) 2.01
The concurrent chemoradiation paradigm--general principles. Nat Clin Pract Oncol (2007) 1.98
Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res (2005) 1.97
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol (2008) 1.91
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol (2007) 1.91
Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol (2010) 1.90
Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys (2005) 1.85
An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol (2003) 1.78
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res (2005) 1.75
Differences in clinical trial patient attributes and outcomes according to enrollment setting. J Clin Oncol (2009) 1.74
Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.70
Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer (2011) 1.70
An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res (2008) 1.68
The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol (2007) 1.67
Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys (2006) 1.66
Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.62
Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res (2008) 1.60
Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA (2005) 1.59
Stereotactic Body Radiation Therapy (SBRT) for lung metastases. Acta Oncol (2006) 1.56
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol (2003) 1.52
Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys (2004) 1.52
The expanding role of systemic therapy in head and neck cancer. J Clin Oncol (2004) 1.50
Cancers of the oral cavity and oropharynx: FDG PET with contrast-enhanced CT in the posttreatment setting. Radiographics (2011) 1.47
Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J Clin Oncol (2011) 1.45
MicroRNA expression characterizes oligometastasis(es). PLoS One (2011) 1.45
Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res (2004) 1.44
Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer. J Thorac Oncol (2006) 1.44
New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. J Clin Oncol (2013) 1.43
Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol (2011) 1.42
Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol (2008) 1.41
Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation. Head Neck (2006) 1.40
Hormone therapy and radiotherapy for early prostate cancer: a utility-adjusted number needed to treat (NNT) analysis. Int J Radiat Oncol Biol Phys (2005) 1.39
Aspiration in chemoradiated patients with head and neck cancer. Arch Otolaryngol Head Neck Surg (2007) 1.39
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol (2012) 1.37
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol (2010) 1.36
Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. J Thorac Oncol (2010) 1.34
Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. Radiology (2010) 1.33
Swallowing dysfunction--preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: a critical review. Int J Radiat Oncol Biol Phys (2003) 1.33
Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Clin Oncol (2005) 1.29
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol (2008) 1.29
Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol (2009) 1.27
EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J Biol Chem (2010) 1.27
Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol (2004) 1.26
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS One (2010) 1.25
Transoral robotic resection and reconstruction for head and neck cancer. Laryngoscope (2011) 1.24
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol (2008) 1.23
Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res (2011) 1.22
Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol (2004) 1.20
A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res (2007) 1.19
Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol (2007) 1.19
A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy. Radiother Oncol (2009) 1.16
Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. Int J Oncol (2006) 1.13
HPV-induced oropharyngeal cancer, immune response and response to therapy. Cancer Lett (2009) 1.13
Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One (2012) 1.11
Stereotactic radiosurgery for glioblastoma: retrospective analysis. Radiat Oncol (2009) 1.11
Prophylactic swallowing exercises in patients with head and neck cancer undergoing chemoradiation: a randomized trial. Arch Otolaryngol Head Neck Surg (2012) 1.11
Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. J Clin Oncol (2009) 1.10
Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol (2004) 1.09